Long‐term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program

Two randomized, double‐blind, placebo‐controlled studies demonstrated responses (≥50 000/μL) to fostamatinib in adults with long‐standing immune thrombocytopenia (ITP). The long‐term safety and efficacy of fostamatinib were evaluated in a follow‐on, open‐label extension (OLE) study. Patients receive...

Descripción completa

Detalles Bibliográficos
Autores principales: Bussel, James B., Arnold, Donald M., Boxer, Michael A., Cooper, Nichola, Mayer, Jiri, Zayed, Hany, Tong, Sandra, Duliege, Anne‐Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6594140/
https://www.ncbi.nlm.nih.gov/pubmed/30784097
http://dx.doi.org/10.1002/ajh.25444

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6594140/
https://www.ncbi.nlm.nih.gov/pubmed/30784097
http://dx.doi.org/10.1002/ajh.25444

Ejemplares similares